GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Net Cash per Share

Kaken Pharmaceutical Co (TSE:4521) Net Cash per Share : 円1,002.12 (As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Kaken Pharmaceutical Co's Net Cash per Share for the quarter that ended in Dec. 2023 was 円1,002.12.

The historical rank and industry rank for Kaken Pharmaceutical Co's Net Cash per Share or its related term are showing as below:

TSE:4521' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.98   Med: 4.46   Max: 155.16
Current: 3.51

During the past 13 years, the highest Price-to-Net-Cash Ratio of Kaken Pharmaceutical Co was 155.16. The lowest was 2.98. And the median was 4.46.

TSE:4521's Price-to-Net-Cash is ranked better than
78.29% of 258 companies
in the Drug Manufacturers industry
Industry Median: 7.655 vs TSE:4521: 3.51

Kaken Pharmaceutical Co Net Cash per Share Historical Data

The historical data trend for Kaken Pharmaceutical Co's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Net Cash per Share Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 596.71 1,128.37 1,310.83 1,247.75 1,179.23

Kaken Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,145.20 1,179.23 1,111.10 1,044.41 1,002.12

Competitive Comparison of Kaken Pharmaceutical Co's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Price-to-Net-Cash falls into.



Kaken Pharmaceutical Co Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Kaken Pharmaceutical Co's Net Cash per Share for the fiscal year that ended in Mar. 2023 is calculated as

Net Cash per Share (A: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(74260-29493-578)/37.4729
=1,179.23

Kaken Pharmaceutical Co's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(66152-28202-0)/37.8699
=1,002.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaken Pharmaceutical Co  (TSE:4521) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Kaken Pharmaceutical Co Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines